The FDA approved tebentafusp-tebn for the treatment of adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma.
Tebentafusp-tebn (Kimmtrak, Immunocore) — the only FDA-approved treatment for this indication — is the first T-cell receptor therapeutic to receive regulatory approval.
Tebentafusp-tebn is a bispecific protein composed of a soluble T-cell receptor fused to an anti-CD3 immune-effector function. The agent targets gp100, a lineage antigen expressed in melanocytes and melanoma.
“Uveal melanoma is a devastating disease that has historically resulted in